10 Jim Cramer Stocks with Huge Upside Potential

Page 9 of 9

1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Average Price Target Upside: 51.41%

Number of Hedge Fund Holders: 68

Last week, recounting stocks with the most gains over the past 20 years, Cramer discussed Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as he said:

“Rearrange Repligen’s ticker just a bit and you’ll get the ninth best stock of the Mad Money era, Regeneron Pharma, that’s up more than 9,400%. Now this one’s special to me because Regeneron’s co-founder and CEO, Dr. Len Schleifer, he was one of the first guests who ever came on the show back in April 12th, 2005. The stock was trading at less than five bucks a share. Now it’s at $568, and that’s after 6.87% beating today.

Regeneron is arguably the most innovative biopharma company I’ve seen in the last two decades. But the stock’s come in significantly over the past eight months or so, falling more than 50% from its highs. Wall Street’s trying to game the impact of Regeneron first big patent cliff as they lost protection for their EYLEA, that’s a blockbuster treatment for wet age-related macular degeneration. In fact, when Regeneron reported this morning, numbers came up a little short because of an EYLEA miss, which is why the stock got clobbered today.”

Regeneron (NASDAQ:REGN) creates and sells medications for various diseases. The company works on discovering new treatments for multiple medical issues. On April 30, Truist revised its price target for REGN, from $975 to $940 while maintaining a Buy rating on the stock. The firm explained that the adjustment shows a more conservative view on Eylea sales in the near term.

Despite the tempered expectations around Eylea, Truist pointed out that Regeneron (NASDAQ:REGN) is still delivering growth on both revenue and earnings fronts, especially driven by the performance of Dupixent (Dupi) and Libtayo. According to the analyst, while the market’s current attention may be centered on the slowing momentum of Eylea, the company’s broader financial outlook remains positive thanks to contributions from its other key products.

While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than REGN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9